This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Mentions of cloud computing within the filings of companies in the pharmaceutical industry rose 65% between the final quarter of 2021 and the first quarter of 2022. To assess whether cloud computing is featuring more in the summaries and strategies of pharmaceuticalcompanies, two measures were calculated.
2 And, as of September 2021, there are 22 COVID-19 vaccines in use globally 3 , and over 2.3 Regulators and pharmaceuticalcompanies are investigating cloud-based platforms to enable the real-time sharing of data. Last accessed: October 2021. Last accessed: October 2021. Last accessed: October 2021.
Pharmaceuticalcompanies will need new standard operating procedures (SOP) to cover activities such as collaborative working, and new documentation to reflect changes in language. While the 2021 version makes provision for support from AQPs, it will take time for these people to be recruited, trained, and monitored. “In
The sampling strategy must be supported by sound and properly cited sources whose conclusions must be presented as supportive elements in the study documents. The following four elements of sampling methodology were found to be under-documented in RMM effectiveness studies: Supporting documentation for country/region selection.
Earlier this month, the World Health Organisation (WHO) released a new guidance document with a strategic plan to counter TB on a national level. Sequella is a US-based pharmaceuticalcompany that develops antibiotics to address drug resistant infections. Sequella is developing SQ-109 for the treatment of pulmonary tuberculosis.
… Pharmaceuticalcompanies could be made to disclose prices and deals for products they make to fight future global health emergencies, under new rules that would govern a World Health Organization-backed pandemic accord , Reuters reports. A Or you may want to take stock of your life. But be safe. Enjoy, and see you soon.
Mentions of robotics within the filings of companies in the pharmaceutical industry fell 22% between the final quarter of 2021 and the first quarter of 2022. To assess whether robotics is featuring more in the summaries and strategies of pharmaceuticalcompanies, two measures were calculated. of all sentences.
In total, the frequency of sentences related to digitalization between July 2021 and June 2022 was 400% higher than in 2016 when GlobalData, from whom our data for this article is taken, first began to track the key issues referred to in company filings. of sentences in the company's filings. of all sentences.
In total, the frequency of sentences related to artificial intelligence between July 2021 and June 2022 was 400% higher than in 2016 when GlobalData, from whom our data for this article is taken, first began to track the key issues referred to in company filings. of sentences in the company's filings. of all sentences.
Mentions of the future of work within the filings of companies in the pharmaceutical industry were 373% higher between April 2021 and March 2022 than in 2016, according to the latest analysis of data from GlobalData. Of the document's 1,725 sentences, seven (0.4%) referred to the future of work.
At this year’s Reuters Pharma Clinical 2021, I joined over 500 global leaders in clinical research as they discussed many of these issues under the theme, “rebuild clinical trials in the image of patient need.”. How do we increase the diversity of clinical trials?
A group of industry experts is set to explore how medical device, clinical trial and pharmaceuticalcompanies can proactively manage labeling risk. Yet no matter the size of company, the principles of validation are the same. Experts to come together for compliance event . Wokingham, United Kingdom —?27?April?2021?—
Having previously spoken with Dr Mullen three years ago when she was country medical director for the UK & Ireland at GSK – on the topic of patient centricity and embedding that focus within the core of a pharmaceuticalcompany – our recent interview provided some interesting insights into the changing landscape of the industry.
IQVIA’s Sarah Rickwood reviews the launch of innovative medicines in 2020 and outlines three key pillars of activity for companies to focus on and address in 2021. Even with the vaccine roll-out, further waves of COVID infection and lockdowns mean these vital drivers of launch performance remain impacted in 2021, and even beyond.
In an era when the world is accelerating the development of drugs and targeted medicines using innovative technologies, pharmaceuticalcompanies still face registration hurdles for well-characterized molecules because of redundant or additional local regulatory requirements.
The European Commission (EC) conducted a comprehensive assessment 1 in 2021 that revealed that 80 percent of API by volume imported into Europe comes from just five countries, with China supplying 45 percent of the API and the rest coming from India, Indonesia, US and UK.
Still, in 2021, we have seen the industry evolve and develop strategies on how to establish a viable ECA. Beyond the FDA, other institutions have documented what industry standards should look like in assessing RWD in a regulatory context. Furthermore, ECAs are well-documented in the post-approval setting.
For pharma, the impact in critical areas such as the performance of newly marketed innovation has already been documented. More remains to be addressed, and not just by conventional pharmaceuticalcompanies. The pause button was on for major acquisitions throughout 2021 and for most of 2022. Pharma boxed in?
This was also one of the key messages from the recent Healthcare Automation and Digitalization Congress (AUTOMA+) 2021, at which I led a round-table discussion on the ‘prevention versus treatment’. For radical innovation thinking to be successful, all healthcare companies and providers must respond and adapt to the patient of the future.
In a more recent report, the ABPI found that the number of Phase III industry trials fell by 48% between 2017 and 2021. At the time of its publication, the document prioritised the finalisation of Brexit above all else. For the life sciences and pharmaceutical sector, the Conservative government promised £34 billion ($38.98
A 2021 study found an estimated $220 billion of medical debt in the United States spread across 20 million people. Here are some things you’ll need to do when filing for bankruptcy: Get your financial documents in order. File the documents in the proper court. Submit the required documents.
Hidden expenses can pile up, spiraling out of control due to many reasons related to supplier performance: the lack of appropriate documentation, storage, wrong dosage forms, and the list goes on. Technologies allow pharmaceuticalcompanies to collect and analyze a massive amount of data to ensure proper drug safety.
These standardised documents provide meticulously curated and scientifically approved information. The responsibility of printing paper leaflets is currently a key regulatory obligation for pharmaceuticalcompanies. Eurostat (2022) “How many citizens had basic digital skills in 2021?”
This article appears in our digital magazine, Deep Dive: Market Access 2021. Practically though, there are risks of additional processes and requirements (and expense) for pharmaceuticalcompanies. Experts from ICON give us their views on the past, present and future of NICE’s standing on the world stage.
1 International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. 1 International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. Published July 2021. ICH Harmonised Tripartite Guideline Q13: Continuous Manufacturing of Drug Substances and Drug Products.”
International convergence is another area in which the FDA is a participant, including in initiatives related to viral safety (ICH Q5A), CM (ICH Q13), quality risk management (QRM; ICH Q9), analytical procedure development (APD; ICH Q2/14), pharmaceutical product life-cycle management (ICH Q12), and common technical document (ICH M4Q).
A collaborative mindset must prevail between pharmaceuticalcompanies, suppliers, and regulators and include strategic partnerships that go beyond the pharmaceutical sector so we can move together to a more sustainable future. The risks are equally applicable to both privately owned and publicly traded companies.
9 December 2021. Increasing the Circularity of Packaging Along Pharmaceuticals Value Chain.” A pharmaceutical quality system (PQS) is a management system used to direct and control a pharmaceuticalcompany with regard to quality. The Global Use of Medicines 2022.” link] 2 Salmenperä, H., Dahlbo, and P.
ChatGPT: “In a pharmaceutical software engineering context, data integrity refers to the accuracy, consistency, and reliability of data stored in computerized systems. This is a crucial aspect of pharmaceutical software as it directly impacts patient safety.
Although there are currently no set metrics or prescribed areas of focus, there are several key areas that pharmaceuticalcompanies can pinpoint when measuring the S in ESG. For pharmaceuticalcompanies, ensuring that human rights are protected by offering transparency and performing due diligence in global supply chains is key.
For example, one pharmaceuticalcompany that switched to CM reported a 50% reduction in operating costs, a 33% reduction in waste, an 80% reduction in manufacturing and testing cycle time, and a 66% reduction in time from testing to release. National Academies Press, 2021. Journal of Pharmaceutical Science (9 January 2023).
A patient access scheme or commercial arrangement associated with the NICE guidance is a way for pharmaceuticalcompanies to lower the acquisition cost to the NHS to improve its cost-effectiveness, so enabling patients to gain access to high-cost medicine treatments. TA681, March 2021. Conclusion. www.nice.org.uk/guidance/ta681
Although it has been widely adopted in other industries, the pharmaceutical industry has yet to do so, and most drug production still relies on the longstanding batch manufacturing process. 3 As the pharmaceutical industry shifts its focus to biologics, the investment in CM elements in industry is expected to increase considerably.
WHO Expert Committee on Specifications for Pharmaceutical Preparations.” Published 2021. Pharmaceutical Engineering 42, no. link] 6 International Pharmaceutical Regulators Programme. IPRP Strategic Vision 2018–2021. WHO Technical Report Series, No. Accessed 14 June 2023. link] 2 a b Ramnarine, E., Edwards, K.
Of the world’s 20 largest pharmaceuticalcompanies, 17 have launched programmes tailored towards increasing medication access in low- and middle-income countries – up from just eight in 2010. Figure 1: Social media posts from pharmaceutical firms mentioning “environment”. A similar theme is evident in company filings.
In April, the pilot-level Nordic Pharmaceutical Forum (NPF) initiative, representing Finland, Iceland, Norway, Sweden, and Denmark, released an updated strategy document outlining the region’s plans to establish a joint procurement mechanism for medicines, with a declared focus on advanced therapy medicinal products (ATMPs) such as gene therapies.
We organize all of the trending information in your field so you don't have to. Join 5,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content